TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25842202
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (demographically similar, N = 32, scanned twice)
Study: 24515256
Drug: Lifestyle counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle counseling (LC) plus metformin (target dose of 1,000 mg twice daily)
Study: 22505373
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate 300 mg q.i.d., esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., and amoxicillin 1 g b.i.d. (bismuth group)
Study: 22505373
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., amoxicillin 1 g b.i.d., and metronidazole 500 mg t.i.d. (concomitant group)
Study: 20386337
Drug: Diabetes medication
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes medication usage and history of cardiovascular disease
Study: 12859471
Drug: 15 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml.kg‐1 Hartmann's solution (supplemental fluid)
Study: 12859471
Drug: 2 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml.kg‐1 Hartmann's solution (conservative fluid)
Study: 10690832
Drug: Intravenous broad-spectrum
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous broad-spectrum antibiotic immediately after induction of anesthesia (group 1)
Study: 10690832
Drug: Postoperative course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative course of oral antibiotics (group 3)
Study: 8645644
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.7 g/day n‐3 fatty acids)
Study: 29953304
Drug: Internet-Based Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-Based Mindfulness-Based Cognitive Therapy (eMBCT)
Study: 27621609
Drug: Albuterol (4×100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (4×100 μg/puff in the UK; 4×90 μg/puff in the US)
Study: 27621609
Drug: Ipratropium (4×20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (4×20 μg/puff)
Study: 23663079
Drug: Sedative music
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative music played for the first hour in bed
Study: 18925392
Drug: Recombinant IL-21
Normalized name: Human il-12 (recombinant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IL-21 (rIL-21) administered by intravenous bolus injection at dose levels from 1 to 100 microg/kg
Study: 18925392
Drug: 5 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 + 9 dosing regimen of rIL-21
Study: 18925392
Drug: 3/w dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3/w dosing regimen of rIL-21
Study: 15378666
Drug: milnacipran (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: milnacipran (up to 200 mg/day)
Study: 15378666
Drug: milnacipran (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: milnacipran (twice daily)
Study: 11556124
Drug: 10 x
Normalized name: PAD,ABDOMINAL 10 X 12 NONSTERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 x 2 mg prednisolone tablets
Study: 11556124
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 5 mg prednisolone tablets
Study: 11556124
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisolone tablet formulation
Study: 3416729
Drug: Alcohol doses
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol doses (0.25, 0.5 and 0.75 g/kg of 95% ethanol)
Study: 29900909
Drug: Chronic generalized
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic generalized periodontitis (Group II) before treatment
Study: 27404009
Drug: Smartphone raffle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone raffle intervention (weekly for clients, monthly for peer promoters and providers)
Study: 24096084
Drug: Purported weight-loss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purported weight-loss supplement (placebo)
Study: 21443756
Drug: Cream A
Normalized name: KIT, CREAM AND GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream A [3% PLA-retinyl retinoate (2%) microsphere] applied twice daily
Study: 21443756
Drug: Cream B
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream B (0.06% retinyl retinoate) applied twice daily
Study: 18753058
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment with directional soft tube placement
Study: 18753058
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (medication)
Study: 12091260
Drug: Citalopram 20-40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20-40 mg for 8 weeks followed by 16 weeks of fixed dose and then randomisation to citalopram for at least 48 weeks
Study: 11185677
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg/day)
Study: 8543937
Drug: Theophylline 150
Normalized name: theophylline 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 150 mg/day
Study: 2037418
Drug: Phenol treatment
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenol treatment on tympanic membrane prior to myringotomy
Study: 2037418
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no phenol treatment)
Study: 7016224
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy alone
Study: 7016224
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy plus living BCG vaccinations
Study: 28115667
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of zinc
Study: 28115667
Drug: Both 2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 2,500 IU of vitamin A and 25 mg of zinc
Study: 25887759
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continuing with the treatment allocated in the ADDITION study
Study: 15972619
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 50 mg injections every 3 weeks
Study: 12812849
Drug: Fractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated stereotactic radiotherapy (SRT) boost to 20 Gy in four fractions following partial brain irradiation to a dose of 60 Gy in 30 fractions
Study: 10319907
Drug: Haloperidol 30
Normalized name: Haloperidol 300 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 30 mg/day plus cyproheptadine 24 mg/day
Study: 10319907
Drug: Haloperidol 30
Normalized name: Haloperidol 300 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 30 mg/day plus placebo
Study: 8532270
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg, three times per day from 36 weeks' gestation until delivery
Study: 3314973
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg
Study: 3066417
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam
Study: 21143248
Drug: L-cysteine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-cysteine (200 mg)
Study: 19321405
Drug: Intravenous gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin
Study: 17156222
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg administered intravenously 30 min before the end of surgery
Study: 17156222
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg administered intravenously 30 min before the end of surgery
Study: 10501408
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antioxidants, niacin, and warfarin
Study: 1681430
Drug: Isoniazid (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (up to 1,200 mg daily) with 100 mg pyridoxine for four weeks
Study: 30328031
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg melatonin once a day
Study: 20976430
Drug: Home visiting
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visiting program 'Pro Kind' (treatment group)
Study: 9851759
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (300 mg, im, every 3 weeks for 6 months)
Study: 26869247
Drug: 2 mg/2
Normalized name: risperidone 2 mg/2 mL ORAL SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/2 mg buprenorphine/samidorphan
Study: 26869247
Drug: 8 mg/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/8 mg buprenorphine/samidorphan
Study: 22302908
Drug: Gabapentin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (oral dose before surgery)
Study: 100808
Drug: Methamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (10 mg)
Study: 15936062
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Methamphetamine (10 mg) and Zolpidem (10 mg)
Study: 10543415
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg medrogestone (Prothil)
Study: 6352020
Drug: Weekly high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly high‐dose asparaginase
Study: 6352020
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (vincristine, prednisone, doxorubicin)
Study: 27049778
Drug: Active Nonoperative
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Nonoperative Therapy (NO) with low-dose neuromodulator (amitriptyline 25 mg/day)
Study: 18709235
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (12.5mg Fe/day)
Study: 18709235
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (25mg Fe/week)
Study: 15957672
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment for female alcoholics
Study: 15957672
Drug: Couple treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple treatment for female alcoholics
Study: 8394861
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (Sbv) at 20 mg/kg/day for 30 days (group S)
Study: 8394861
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (Sbv) at 20 mg/kg/day plus aminosidine at 15 mg/kg/day for 17 days (group AS)
Study: 3089361
Drug: Nystatin suspension
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin suspension or pastilles (new formulation)
Study: 3089361
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment of dentures
Study: 18280835
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, sc 66 µg/Kg/d
Study: 17128839
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) vaccination (40 microgram, 2 ml)
Study: 17128839
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) vaccination (10 microgram, 0.5 ml)
Study: 17128839
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) vaccination (10 microgram, 0.5 ml)
Study: 31178989
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy (OT) + Virtual Reality (VR)
Study: 24597840
Drug: Luseogliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (all doses)
Study: 19049846
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg)
Study: 16366812
Drug: Adolescent Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent Drug Abuse Diagnosis Scale self-report measure
Study: 12163983
Drug: Mg(2+) supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg(2+) supplementation (10 mmol for 3 days, 20 mmol for 3 days, 30 mmol for 14 days)
Study: 12163983
Drug: Mg(2+) supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg(2+) supplementation
Study: 9588417
Drug: Intraaortic balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraaortic balloon counterpulsation (IABC) with 20 ml inflation volume
Study: 9588417
Drug: Intraaortic balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraaortic balloon counterpulsation (IABC) with 40 ml inflation volume
Study: 8560129
Drug: Temazepam 15-30
Normalized name: temazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 15-30 mg/day
Study: 8560129
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or behavior therapy
Study: 22659250
Drug: T-gel
Normalized name: Neutrogena T-Gel Conditioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-gel
Study: 22659250
Drug: T-gel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-gel + DMPA
Study: 22659250
Drug: T-gel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-gel + dutasteride
Study: 20084316
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (weekly sessions for twelve weeks)
Study: 15381386
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment (75 mg/day; 7 days)
Study: 11432884
Drug: Initial lumbar
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial lumbar puncture and intrathecal chemotherapy performed after 1 week of prednisolone sensitivity testing (day 8).
Study: 7983234
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg nitroglycerin (NTG) sublingually
Study: 2590601
Drug: Phentolamine 5
Normalized name: phentolamine 5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine 5 mg i.v.
Study: 31589615
Drug: Alpha-adrenergic blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenergic blockers
Study: 25766261
Drug: Glucose-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based therapy
Study: 25766261
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of glucose-sparing regimen vs glucose-based therapy
Study: 10740421
Drug: Leaving patients
Normalized name: digitalis leaves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaving patients with atrial fibrillation (AF) treated by rate control and antithrombotic treatment
Study: 10684783
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg)
Study: 7098380
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous (IV) propranolol
Study: 7098380
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oral propranolol
Study: 7098380
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oral propranolol (multiple doses every 12 h)
Study: 7098380
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oral propranolol (single dose)
Study: 25934242
Drug: Lumboperitoneal shunt
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumboperitoneal shunt surgery (immediate treatment group)
Study: 25934242
Drug: Postponed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postponed treatment group (surgery postponed for 3 months)
Study: 20622199
Drug: Golimumab plus
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab plus methotrexate (background therapy) every 4 weeks through week 52
Study: 20622199
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus methotrexate (background therapy) every 4 weeks through week 52
Study: 11504165
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg once a day)
Study: 7934974
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (continuous intravenous infusion)
Study: 29146648
Drug: E-PsEYE e-mental
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-PsEYE e-mental health intervention based on cognitive-behavioral therapy (CBT) with nine modules delivered in a stepped-care model.
Study: 26592061
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (12 weekly messages)
Study: 23440247
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 µg once daily
Study: 23440247
Drug: FF/VI 200/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 200/25 µg once daily
Study: 23440247
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 µg twice daily
Study: 15224654
Drug: Intra-uterine system
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-uterine system releasing 10 micrograms/day levonorgestrel and 2 mg oral estradiol (trial 1)
Study: 15224654
Drug: Intrauterine system
Normalized name: Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine system releasing 20 micrograms/day levonorgestrel and 2 mg estradiol (trial 2)
Study: 15224654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 mg norethisterone acetate and 2 mg estradiol (trial 2)
Study: 9203809
Drug: Imidazole salycilate
Normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidazole salycilate (IS) 1,500 mg acute dose
Study: 9203809
Drug: Imidazole salycilate
Normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidazole salycilate (IS) 750 mg t.i.d. for 15 days
Study: 9203809
Drug: Imidazole salycilate
Normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidazole salycilate (IS) 750 mg t.i.d. for 30 days
Study: 2735733
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg per day of trimetazidine (TMZ)
Study: 30674586
Drug: Inhaled lipopolysaccharide
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lipopolysaccharide (LPS) 50 µg
Study: 21693044
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy with night-splinting
Study: 21693044
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy only
Study: 16456637
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent glycerine trinitrate ointment applied three times daily at the anal margin for eight weeks (Group A)
Study: 16456637
Drug: 20 units
Normalized name: Omnipod GO 20 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 units Botulinum toxin A injection into the internal anal sphincter on each side of the anterior midline (Group B)
Study: 25635420
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Study: 25635420
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Study: 25635420
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Study: 25635420
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Study: 24996507
Drug: ω‐3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFAs (eicosapentaenoic acid 2g/day and docosahexaenoic acid 1g/day) + α‐LA 300 mg/day
Study: 15179406
Drug: ABT-773 450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-773 450 mg in CYP3A5-negative subjects (n = 9)
Study: 15179406
Drug: ABT-773 450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-773 450 mg in CYP3A5-positive subjects (n = 8)
Study: 15179406
Drug: ABT-773 150
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-773 150 mg or 300 mg
Study: 11455374
Drug: Antimicrobial varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial varnish in combination with fluoride varnish (group 1)
Study: 11455374
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antimicrobial and fluoride varnishes